Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alferminogene tadenovec
- Development stage
- Phase 3
- Lead developer
- Cardium Therapeutics
- Modality
- Gene Therapies
- Administration
- Intracoronary
01
Overview
Alferminogene tadenovec is an investigational gene therapy designed to promote angiogenesis and improve blood flow in patients with myocardial ischemia and angina associated with coronary artery disease. It consists of a replication-deficient human adenovirus serotype 5 vector encoding the human fibroblast growth factor 4 (FGF4) gene, which stimulates the formation of new collateral blood vessels in the heart. The drug is administered via intracoronary infusion, aiming to enhance natural vascular repair mechanisms where native vessel formation is insufficient. Clinical trials have shown that alferminogene tadenovec can increase exercise capacity and myocardial perfusion, particularly benefiting female patients with stable angina who are not candidates for revascularization[1][2][6][7].
- Brand names
- GenerxCardionovo
- Other names
- angiogenic gene therapyFGF4 gene therapyFGF-4 gene therapyFGF 4 gene therapyFGF4 angiogenic DNAFGF-4 angiogenic DNAFGF 4 angiogenic DNAfibroblast growth factor 4 gene therapy
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on alferminogene tadenovec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alferminogene tadenovec.